missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human Annexin A3 (aa 128-268) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (94%), Rat (94%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-82483 (PA5-82483. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
This gene encodes a member of the annexin family. Members of this calcium-dependent phospholipid-binding protein family play a role in the regulation of cellular growth and in signal transduction pathways. This protein functions in the inhibition of phopholipase A2 and cleavage of inositol 1,2-cyclic phosphate to form inositol 1-phosphate. This protein may also play a role in anti-coagulation.
Specifications
Specifications
| Accession Number | P12429 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 306 |
| Name | Human Annexin A3 (aa 128-268) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 35-alpha calcimedin; Annexin 3; annexin A3; Annexin III; Annexin III (Lipocortin III); annexin III (lipocortin III, 1,2-cyclic-inositol-phosphate phosphodiesterase, placental anticoagulant protein III, calcimedin 35-alpha); Annexin3; annexin-3; ANX3; ANXA 3; ANXA3; calcimedin 35-alpha; inositol 1,2-cyclic phosphate 2-phosphohydrolase; LC3; Lipocortin III; LRRGT00047; PAP-III; Placental anticoagulant protein III |
| Common Name | Annexin A3 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction